Akarna Therapeutics, a startup developing drugs targeting inflammatory and fibrotic diseases with no approved treatments, has raised $15 million in a Series B financing.

The round was backed by a new investor, Forbion Capital Partners, and existing investors New Science Ventures and Third Point Ventures.

Akarna, which has offices in San Diego and Cambridge, England, is moving its lead candidate through proof-of-concept studies in patients with nonalcoholic steatohepatitis (NASH), a progressive fatty-liver disease associated with diabetes and obesity.